Stem definition | Drug id | CAS RN |
---|---|---|
diuretics, piretanide derivatives | 427 | 28395-03-1 |
Dose | Unit | Route |
---|---|---|
1 | mg | O |
1 | mg | P |
1 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 45 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.46 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.16 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.03 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 28, 1983 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure congestive | 217.26 | 12.95 | 241 | 24605 | 92516 | 53231704 |
Acute kidney injury | 211.07 | 12.95 | 403 | 24443 | 253465 | 53070755 |
Fluid retention | 200.72 | 12.95 | 181 | 24665 | 54220 | 53270000 |
Fluid overload | 180.65 | 12.95 | 129 | 24717 | 27702 | 53296518 |
Dyspnoea | 165.66 | 12.95 | 622 | 24224 | 585610 | 52738610 |
Right ventricular failure | 125.51 | 12.95 | 85 | 24761 | 16758 | 53307462 |
Rheumatoid arthritis | 115.61 | 12.95 | 8 | 24838 | 314523 | 53009697 |
Pulmonary arterial hypertension | 111.48 | 12.95 | 96 | 24750 | 27026 | 53297194 |
Pulmonary hypertension | 106.96 | 12.95 | 108 | 24738 | 37162 | 53287058 |
Oedema peripheral | 106.23 | 12.95 | 241 | 24605 | 170546 | 53153674 |
Drug ineffective | 99.77 | 12.95 | 142 | 24704 | 817103 | 52507117 |
Renal failure | 94.36 | 12.95 | 185 | 24661 | 118267 | 53205953 |
Oedema | 93.26 | 12.95 | 142 | 24704 | 74204 | 53250016 |
Cardiac failure | 91.23 | 12.95 | 152 | 24694 | 85692 | 53238528 |
Body tinea | 78.25 | 12.95 | 27 | 24819 | 1174 | 53323046 |
International normalised ratio increased | 77.24 | 12.95 | 103 | 24743 | 47658 | 53276562 |
Renal impairment | 71.06 | 12.95 | 134 | 24712 | 83184 | 53241036 |
Off label use | 65.75 | 12.95 | 74 | 24772 | 472138 | 52852082 |
Atrial fibrillation | 65.41 | 12.95 | 154 | 24692 | 111498 | 53212722 |
Infection susceptibility increased | 58.68 | 12.95 | 27 | 24819 | 2510 | 53321710 |
Inhibitory drug interaction | 58.12 | 12.95 | 26 | 24820 | 2264 | 53321956 |
Hyperkalaemia | 54.86 | 12.95 | 94 | 24752 | 54162 | 53270058 |
Pulmonary oedema | 54.22 | 12.95 | 93 | 24753 | 53630 | 53270590 |
Impaired quality of life | 52.35 | 12.95 | 31 | 24815 | 4840 | 53319380 |
Hypotension | 50.50 | 12.95 | 243 | 24603 | 253833 | 53070387 |
Treatment failure | 47.89 | 12.95 | 3 | 24843 | 128400 | 53195820 |
Infusion related reaction | 47.07 | 12.95 | 8 | 24838 | 155949 | 53168271 |
Purpura | 45.77 | 12.95 | 39 | 24807 | 10814 | 53313406 |
Glucose tolerance impaired | 44.83 | 12.95 | 29 | 24817 | 5291 | 53318929 |
Joint swelling | 43.28 | 12.95 | 28 | 24818 | 234610 | 53089610 |
Death | 43.01 | 12.95 | 299 | 24547 | 356933 | 52967287 |
Exposure during pregnancy | 40.94 | 12.95 | 5 | 24841 | 124855 | 53199365 |
Gastrointestinal haemorrhage | 40.86 | 12.95 | 105 | 24741 | 80225 | 53243995 |
Alopecia | 40.60 | 12.95 | 30 | 24816 | 234553 | 53089667 |
Dyspnoea exertional | 40.26 | 12.95 | 83 | 24763 | 54917 | 53269303 |
Cellulitis | 39.35 | 12.95 | 100 | 24746 | 75889 | 53248331 |
Chronic obstructive pulmonary disease | 38.78 | 12.95 | 87 | 24759 | 60986 | 53263234 |
Bradycardia | 37.30 | 12.95 | 94 | 24752 | 70962 | 53253258 |
BRASH syndrome | 37.11 | 12.95 | 10 | 24836 | 185 | 53324035 |
Cardiac failure acute | 36.97 | 12.95 | 32 | 24814 | 9060 | 53315160 |
Hypoxia | 36.12 | 12.95 | 80 | 24766 | 55600 | 53268620 |
Drug intolerance | 35.92 | 12.95 | 26 | 24820 | 205467 | 53118753 |
Left ventricular failure | 35.22 | 12.95 | 25 | 24821 | 5308 | 53318912 |
Contraindicated product administered | 34.79 | 12.95 | 10 | 24836 | 135619 | 53188601 |
Therapeutic product effect decreased | 34.65 | 12.95 | 8 | 24838 | 125647 | 53198573 |
Transfusion | 32.72 | 12.95 | 36 | 24810 | 13651 | 53310569 |
Arthropathy | 31.84 | 12.95 | 13 | 24833 | 141440 | 53182780 |
Congestive cardiomyopathy | 29.93 | 12.95 | 24 | 24822 | 6114 | 53318106 |
Pleural effusion | 29.87 | 12.95 | 100 | 24746 | 88479 | 53235741 |
Dialysis | 29.70 | 12.95 | 30 | 24816 | 10312 | 53313908 |
Blood creatinine increased | 29.37 | 12.95 | 95 | 24751 | 82567 | 53241653 |
Haemoglobin decreased | 28.44 | 12.95 | 133 | 24713 | 137174 | 53187046 |
Respiratory failure | 28.34 | 12.95 | 107 | 24739 | 100405 | 53223815 |
Epistaxis | 28.16 | 12.95 | 83 | 24763 | 68627 | 53255593 |
Hepatic enzyme increased | 27.75 | 12.95 | 12 | 24834 | 126183 | 53198037 |
Gout | 26.88 | 12.95 | 31 | 24815 | 12368 | 53311852 |
Weight increased | 26.20 | 12.95 | 174 | 24672 | 204393 | 53119827 |
Blood potassium decreased | 26.08 | 12.95 | 58 | 24788 | 40402 | 53283818 |
Pain in jaw | 25.88 | 12.95 | 58 | 24788 | 40611 | 53283609 |
Drug hypersensitivity | 25.78 | 12.95 | 53 | 24793 | 265189 | 53059031 |
Acute respiratory failure | 25.05 | 12.95 | 49 | 24797 | 31209 | 53293011 |
Pneumonia | 24.77 | 12.95 | 294 | 24552 | 406875 | 52917345 |
Bone density decreased | 24.56 | 12.95 | 28 | 24818 | 11036 | 53313184 |
Arthralgia | 23.61 | 12.95 | 115 | 24731 | 439668 | 52884552 |
Dehydration | 22.62 | 12.95 | 145 | 24701 | 168265 | 53155955 |
Genital infection female | 22.06 | 12.95 | 6 | 24840 | 115 | 53324105 |
Oxygen saturation decreased | 21.89 | 12.95 | 82 | 24764 | 76643 | 53247577 |
Cardiorenal syndrome | 21.71 | 12.95 | 9 | 24837 | 650 | 53323570 |
Therapeutic product effect incomplete | 21.36 | 12.95 | 8 | 24838 | 91776 | 53232444 |
Rectal haemorrhage | 20.85 | 12.95 | 54 | 24792 | 41427 | 53282793 |
Drug abuse | 20.57 | 12.95 | 3 | 24843 | 65523 | 53258697 |
Anaemia | 20.57 | 12.95 | 208 | 24638 | 276510 | 53047710 |
Hospitalisation | 20.35 | 12.95 | 76 | 24770 | 70936 | 53253284 |
Hyperlipidaemia | 19.96 | 12.95 | 34 | 24812 | 19481 | 53304739 |
Orthopnoea | 19.94 | 12.95 | 19 | 24827 | 6085 | 53318135 |
Chronic left ventricular failure | 19.84 | 12.95 | 7 | 24839 | 325 | 53323895 |
Arteriosclerosis coronary artery | 19.80 | 12.95 | 22 | 24824 | 8432 | 53315788 |
Musculoskeletal stiffness | 19.79 | 12.95 | 17 | 24829 | 123351 | 53200869 |
Blood urea increased | 19.68 | 12.95 | 40 | 24806 | 26191 | 53298029 |
Unevaluable event | 19.53 | 12.95 | 59 | 24787 | 49439 | 53274781 |
Blood potassium increased | 19.47 | 12.95 | 32 | 24814 | 17809 | 53306411 |
Torsade de pointes | 19.42 | 12.95 | 27 | 24819 | 12978 | 53311242 |
Atrial flutter | 19.17 | 12.95 | 23 | 24823 | 9568 | 53314652 |
Intentional overdose | 19.09 | 12.95 | 4 | 24842 | 67201 | 53257019 |
Poor quality sleep | 18.81 | 12.95 | 31 | 24815 | 17292 | 53306928 |
Abdominal distension | 18.54 | 12.95 | 80 | 24766 | 79710 | 53244510 |
Paracentesis | 18.43 | 12.95 | 9 | 24837 | 955 | 53323265 |
Chronic kidney disease | 18.35 | 12.95 | 53 | 24793 | 43317 | 53280903 |
Cardiomegaly | 18.19 | 12.95 | 31 | 24815 | 17769 | 53306451 |
Suicide attempt | 17.50 | 12.95 | 3 | 24843 | 58165 | 53266055 |
Skin disorder | 17.48 | 12.95 | 37 | 24809 | 24921 | 53299299 |
Urine output decreased | 17.16 | 12.95 | 24 | 24822 | 11599 | 53312621 |
Asthenia | 17.03 | 12.95 | 239 | 24607 | 343351 | 52980869 |
Blood aldosterone abnormal | 16.69 | 12.95 | 4 | 24842 | 45 | 53324175 |
Diaphragmatic disorder | 16.66 | 12.95 | 7 | 24839 | 523 | 53323697 |
Impaired work ability | 16.37 | 12.95 | 26 | 24820 | 14064 | 53310156 |
Generalised oedema | 16.37 | 12.95 | 27 | 24819 | 15072 | 53309148 |
Packed red blood cell transfusion | 16.12 | 12.95 | 11 | 24835 | 2192 | 53322028 |
Pemphigoid | 15.49 | 12.95 | 17 | 24829 | 6427 | 53317793 |
Brain natriuretic peptide increased | 15.47 | 12.95 | 15 | 24831 | 4910 | 53319310 |
Wound | 15.45 | 12.95 | 12 | 24834 | 91545 | 53232675 |
Lactic acidosis | 15.25 | 12.95 | 45 | 24801 | 37208 | 53287012 |
Lung transplant | 15.09 | 12.95 | 12 | 24834 | 3022 | 53321198 |
Liver function test abnormal | 15.08 | 12.95 | 53 | 24793 | 48018 | 53276202 |
Oxygen consumption increased | 14.87 | 12.95 | 13 | 24833 | 3728 | 53320492 |
Blood sodium decreased | 14.74 | 12.95 | 33 | 24813 | 23083 | 53301137 |
Claudication of jaw muscles | 14.60 | 12.95 | 4 | 24842 | 79 | 53324141 |
Urosepsis | 14.49 | 12.95 | 27 | 24819 | 16583 | 53307637 |
Sinusitis | 14.47 | 12.95 | 36 | 24810 | 168528 | 53155692 |
Injection site pain | 14.41 | 12.95 | 19 | 24827 | 113372 | 53210848 |
Compartment syndrome | 14.40 | 12.95 | 10 | 24836 | 2051 | 53322169 |
Discomfort | 14.30 | 12.95 | 14 | 24832 | 95458 | 53228762 |
Product use in unapproved indication | 14.08 | 12.95 | 19 | 24827 | 112270 | 53211950 |
Right ventricular dysfunction | 14.07 | 12.95 | 9 | 24837 | 1610 | 53322610 |
Malignant neoplasm progression | 13.92 | 12.95 | 8 | 24838 | 71533 | 53252687 |
Abdominal discomfort | 13.52 | 12.95 | 55 | 24791 | 221007 | 53103213 |
Product use issue | 13.45 | 12.95 | 28 | 24818 | 139556 | 53184664 |
Diuretic therapy | 13.38 | 12.95 | 4 | 24842 | 109 | 53324111 |
Brain stem stroke | 13.35 | 12.95 | 5 | 24841 | 276 | 53323944 |
Incarcerated umbilical hernia | 13.33 | 12.95 | 3 | 24843 | 25 | 53324195 |
Seizure | 13.32 | 12.95 | 25 | 24821 | 129484 | 53194736 |
Drug monitoring procedure not performed | 13.30 | 12.95 | 6 | 24840 | 533 | 53323687 |
Injection site erythema | 13.19 | 12.95 | 10 | 24836 | 77239 | 53246981 |
Pain | 13.16 | 12.95 | 194 | 24652 | 588204 | 52736016 |
Subacute cutaneous lupus erythematosus | 13.15 | 12.95 | 10 | 24836 | 2358 | 53321862 |
Hypersensitivity | 13.14 | 12.95 | 52 | 24794 | 210613 | 53113607 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 208.04 | 13.32 | 513 | 19374 | 292955 | 32200684 |
Cardiac failure congestive | 172.66 | 13.32 | 235 | 19652 | 84617 | 32409022 |
Cardiac failure | 136.12 | 13.32 | 219 | 19668 | 91454 | 32402185 |
Fluid retention | 113.08 | 13.32 | 108 | 19779 | 26442 | 32467197 |
Dyspnoea | 110.58 | 13.32 | 475 | 19412 | 361570 | 32132069 |
Pulmonary hypertension | 82.79 | 13.32 | 81 | 19806 | 20413 | 32473226 |
Oedema peripheral | 67.46 | 13.32 | 187 | 19700 | 113904 | 32379735 |
Fluid overload | 67.30 | 13.32 | 71 | 19816 | 19550 | 32474089 |
Pulmonary arterial hypertension | 45.72 | 13.32 | 42 | 19845 | 9779 | 32483860 |
Drug ineffective | 45.59 | 13.32 | 105 | 19782 | 383372 | 32110267 |
Oedema | 44.05 | 13.32 | 90 | 19797 | 45057 | 32448582 |
Venous pressure jugular increased | 43.73 | 13.32 | 17 | 19870 | 787 | 32492852 |
Right ventricular failure | 40.97 | 13.32 | 37 | 19850 | 8426 | 32485213 |
Renal failure | 39.59 | 13.32 | 175 | 19712 | 134303 | 32359336 |
Blood ketone body increased | 37.94 | 13.32 | 13 | 19874 | 418 | 32493221 |
Glomerular filtration rate decreased | 36.38 | 13.32 | 42 | 19845 | 12769 | 32480870 |
Blood potassium increased | 36.29 | 13.32 | 48 | 19839 | 16756 | 32476883 |
International normalised ratio increased | 33.61 | 13.32 | 85 | 19802 | 48950 | 32444689 |
Toxicity to various agents | 33.19 | 13.32 | 36 | 19851 | 178005 | 32315634 |
Hyperkalaemia | 31.43 | 13.32 | 104 | 19783 | 69646 | 32423993 |
Hypotension | 30.38 | 13.32 | 231 | 19656 | 215879 | 32277760 |
Renal impairment | 30.38 | 13.32 | 124 | 19763 | 91848 | 32401791 |
Venous pressure jugular decreased | 29.68 | 13.32 | 7 | 19880 | 54 | 32493585 |
Peripheral swelling | 29.11 | 13.32 | 100 | 19787 | 68245 | 32425394 |
Hepatic cytolysis | 28.29 | 13.32 | 30 | 19857 | 8303 | 32485336 |
Cardiac failure chronic | 28.08 | 13.32 | 28 | 19859 | 7212 | 32486427 |
Gastrointestinal haemorrhage | 27.79 | 13.32 | 116 | 19771 | 86766 | 32406873 |
Ventricular tachycardia | 27.38 | 13.32 | 53 | 19834 | 25503 | 32468136 |
Off label use | 27.38 | 13.32 | 96 | 19791 | 306224 | 32187415 |
Febrile neutropenia | 27.27 | 13.32 | 20 | 19867 | 119546 | 32374093 |
Completed suicide | 26.03 | 13.32 | 12 | 19875 | 92505 | 32401134 |
Pyrexia | 25.54 | 13.32 | 105 | 19782 | 319863 | 32173776 |
Pulmonary oedema | 25.48 | 13.32 | 74 | 19813 | 46193 | 32447446 |
Blood pressure systolic decreased | 25.43 | 13.32 | 21 | 19866 | 4242 | 32489397 |
Dyspnoea paroxysmal nocturnal | 24.93 | 13.32 | 14 | 19873 | 1503 | 32492136 |
Blood creatinine increased | 24.50 | 13.32 | 120 | 19767 | 96012 | 32397627 |
Orthopnoea | 24.15 | 13.32 | 22 | 19865 | 5065 | 32488574 |
Atrial fibrillation | 23.15 | 13.32 | 136 | 19751 | 116568 | 32377071 |
Dyspnoea exertional | 23.10 | 13.32 | 64 | 19823 | 38897 | 32454742 |
Neutropenia | 22.06 | 13.32 | 33 | 19854 | 142142 | 32351497 |
Pulmonary renal syndrome | 21.88 | 13.32 | 7 | 19880 | 181 | 32493458 |
Weight increased | 21.72 | 13.32 | 105 | 19782 | 83558 | 32410081 |
Vasculitic rash | 21.69 | 13.32 | 11 | 19876 | 961 | 32492678 |
Orthostatic hypotension | 21.39 | 13.32 | 48 | 19839 | 25602 | 32468037 |
Dizziness | 20.53 | 13.32 | 207 | 19680 | 209411 | 32284228 |
Cardiac failure acute | 20.32 | 13.32 | 28 | 19859 | 10156 | 32483483 |
Hepatic cirrhosis | 19.41 | 13.32 | 36 | 19851 | 16773 | 32476866 |
Packed red blood cell transfusion | 18.69 | 13.32 | 12 | 19875 | 1642 | 32491997 |
Chronic kidney disease | 18.34 | 13.32 | 60 | 19827 | 39915 | 32453724 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 18.22 | 13.32 | 9 | 19878 | 744 | 32492895 |
Rheumatoid arthritis | 17.64 | 13.32 | 3 | 19884 | 44541 | 32449098 |
Amyloidosis | 17.49 | 13.32 | 13 | 19874 | 2253 | 32491386 |
Weight bearing difficulty | 16.58 | 13.32 | 9 | 19878 | 904 | 32492735 |
Transitional cell carcinoma | 15.97 | 13.32 | 12 | 19875 | 2115 | 32491524 |
Reaction to excipient | 15.93 | 13.32 | 7 | 19880 | 443 | 32493196 |
Bradycardia | 15.90 | 13.32 | 86 | 19801 | 71476 | 32422163 |
Hypovolaemia | 15.64 | 13.32 | 23 | 19864 | 8854 | 32484785 |
Death | 15.00 | 13.32 | 322 | 19565 | 382195 | 32111444 |
Treatment failure | 14.73 | 13.32 | 3 | 19884 | 39160 | 32454479 |
Hospitalisation | 14.57 | 13.32 | 64 | 19823 | 48907 | 32444732 |
Polyuria | 14.52 | 13.32 | 21 | 19866 | 7964 | 32485675 |
Suicide attempt | 14.24 | 13.32 | 3 | 19884 | 38241 | 32455398 |
Brain natriuretic peptide abnormal | 14.07 | 13.32 | 6 | 19881 | 353 | 32493286 |
Sinus bradycardia | 14.06 | 13.32 | 27 | 19860 | 12911 | 32480728 |
Abdominal cavity drainage | 14.02 | 13.32 | 6 | 19881 | 356 | 32493283 |
Hepatic function abnormal | 13.93 | 13.32 | 5 | 19882 | 44835 | 32448804 |
Ascites | 13.90 | 13.32 | 55 | 19832 | 40136 | 32453503 |
Haemoglobin decreased | 13.58 | 13.32 | 122 | 19765 | 119549 | 32374090 |
Blood urea increased | 13.53 | 13.32 | 47 | 19840 | 32226 | 32461413 |
Neutrophil count decreased | 13.43 | 13.32 | 6 | 19881 | 47133 | 32446506 |
Source | Code | Description |
---|---|---|
ATC | C03CA02 | CARDIOVASCULAR SYSTEM DIURETICS HIGH-CEILING DIURETICS Sulfonamides, plain |
ATC | C03CB02 | CARDIOVASCULAR SYSTEM DIURETICS HIGH-CEILING DIURETICS Sulfonamides and potassium in combination |
ATC | C03EB02 | CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION High-ceiling diuretics and potassium-sparing agents |
FDA PE | N0000175366 | Increased Diuresis at Loop of Henle |
FDA EPC | N0000175590 | Loop Diuretic |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:131770 | cystic fibrosis transmembrane conductance regulator inhibitors |
MeSH PA | D004232 | Diuretics |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D045283 | Natriuretic Agents |
MeSH PA | D049994 | Sodium Potassium Chloride Symporter Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Edema | indication | 267038008 | |
Edema due to Hepatic Cirrhosis | indication | ||
Peripheral Edema due to Chronic Heart Failure | indication | ||
Renal Disease with Edema | indication | ||
Pulmonary Edema due to Chronic Heart Failure | indication | ||
Hypertensive disorder | off-label use | 38341003 | DOID:10763 |
Hypercalcemia | off-label use | 66931009 | DOID:12678 |
Decompensated cardiac failure | off-label use | 195111005 | |
Anuria | contraindication | 2472002 | DOID:2983 |
Hypocalcemia | contraindication | 5291005 | |
Hypovolemia | contraindication | 28560003 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Hypokalemia | contraindication | 43339004 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Oliguria | contraindication | 83128009 | |
Hearing disorder | contraindication | 128540005 | |
Hypomagnesemia | contraindication | 190855004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.36 | acidic |
pKa2 | 9.88 | acidic |
pKa3 | 0.86 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 12 member 1 | Transporter | INHIBITOR | Ki | 7.60 | WOMBAT-PK | CHEMBL | |||
Sodium/potassium-transporting ATPase subunit alpha-1 | Transporter | Kd | 7.52 | WOMBAT-PK | |||||
Solute carrier family 12 member 2 | Transporter | INHIBITOR | IC50 | 5.60 | IUPHAR | ||||
G-protein coupled receptor 35 | GPCR | AGONIST | EC50 | 5.54 | IUPHAR |
ID | Source |
---|---|
4017794 | VUID |
N0000146155 | NUI |
D00247 | KEGG_DRUG |
C0006376 | UMLSCUI |
CHEBI:3213 | CHEBI |
CHEMBL1072 | ChEMBL_ID |
DB00887 | DRUGBANK_ID |
D002034 | MESH_DESCRIPTOR_UI |
2471 | PUBCHEM_CID |
4837 | IUPHAR_LIGAND_ID |
2943 | INN_ID |
0Y2S3XUQ5H | UNII |
1808 | RXNORM |
3606 | MMSL |
4304 | MMSL |
d00179 | MMSL |
002312 | NDDF |
387498005 | SNOMEDCT_US |
86647004 | SNOMEDCT_US |
4017794 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0128 | TABLET | 0.50 mg | ORAL | ANDA | 21 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0129 | TABLET | 1 mg | ORAL | ANDA | 21 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0130 | TABLET | 2 mg | ORAL | ANDA | 21 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1412 | INJECTION, SOLUTION | 0.25 mg | INTRAMUSCULAR | ANDA | 20 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8361 | TABLET | 1 mg | ORAL | ANDA | 20 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8362 | TABLET | 2 mg | ORAL | ANDA | 20 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8393 | TABLET | 1 mg | ORAL | ANDA | 21 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8394 | TABLET | 2 mg | ORAL | ANDA | 21 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6007 | INJECTION | 0.25 mg | INTRAMUSCULAR | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6008 | INJECTION | 0.25 mg | INTRAMUSCULAR | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6161 | INJECTION | 0.25 mg | INTRAMUSCULAR | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6162 | INJECTION | 0.25 mg | INTRAMUSCULAR | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0540 | TABLET | 0.50 mg | ORAL | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0541 | TABLET | 1 mg | ORAL | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0542 | TABLET | 2 mg | ORAL | ANDA | 22 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7016 | TABLET | 1 mg | ORAL | ANDA | 21 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-700 | TABLET | 0.50 mg | ORAL | ANDA | 19 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-701 | TABLET | 1 mg | ORAL | ANDA | 19 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-702 | TABLET | 2 mg | ORAL | ANDA | 19 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-831 | TABLET | 0.50 mg | ORAL | ANDA | 18 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-832 | TABLET | 1 mg | ORAL | ANDA | 18 sections |
bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-833 | TABLET | 2 mg | ORAL | ANDA | 18 sections |
Bumex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30698-630 | TABLET | 0.50 mg | ORAL | NDA | 21 sections |
Bumex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30698-631 | TABLET | 1 mg | ORAL | NDA | 21 sections |
Bumex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30698-632 | TABLET | 2 mg | ORAL | NDA | 21 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-983 | TABLET | 1 mg | ORAL | ANDA | 20 sections |
Bumetanide | Human Prescription Drug Label | 1 | 42799-119 | TABLET | 0.50 mg | ORAL | NDA AUTHORIZED GENERIC | 23 sections |
Bumetanide | Human Prescription Drug Label | 1 | 42799-120 | TABLET | 1 mg | ORAL | NDA AUTHORIZED GENERIC | 23 sections |
Bumetanide | Human Prescription Drug Label | 1 | 42799-121 | TABLET | 2 mg | ORAL | NDA AUTHORIZED GENERIC | 23 sections |
Bumetanide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-288 | TABLET | 1 mg | ORAL | ANDA | 21 sections |